Evidence map›Paper›PMID 41230741›Full record

ArticleThe Journal of pathology2026

Generation of functional noncanonical donor splice sites by +2T variants in breast cancer susceptibility genes: impact on clinical interpretation.

Inés Llinares-Burguet, Lara Sanoguera-Miralles, Elena Bueno-Martínez, Alicia García-Álvarez, Alberto Valenzuela-Palomo, Pedro Pérez-Segura, Miguel de la Hoya, Eladio A Velasco-Sampedro

Abstract read
In one paragraph

Article in The Journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Inés Llinares-BurguetSplicing and genetic susceptibility to cancer. Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM). Consejo Superior de Investigaciones Científicas - Universidad de Valladolid (CSIC-UVa), Valladolid, Spain.ORCID https://orcid.org/0000-0002-7838-0838
Lara Sanoguera-MirallesSplicing and genetic susceptibility to cancer. Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM). Consejo Superior de Investigaciones Científicas - Universidad de Valladolid (CSIC-UVa), Valladolid, Spain.
Elena Bueno-MartínezSplicing and genetic susceptibility to cancer. Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM). Consejo Superior de Investigaciones Científicas - Universidad de Valladolid (CSIC-UVa), Valladolid, Spain.
Alicia García-ÁlvarezSplicing and genetic susceptibility to cancer. Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM). Consejo Superior de Investigaciones Científicas - Universidad de Valladolid (CSIC-UVa), Valladolid, Spain.
Alberto Valenzuela-PalomoSplicing and genetic susceptibility to cancer. Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM). Consejo Superior de Investigaciones Científicas - Universidad de Valladolid (CSIC-UVa), Valladolid, Spain.
Pedro Pérez-SeguraMolecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.
Miguel de la HoyaMolecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.
Eladio A Velasco-SampedroSplicing and genetic susceptibility to cancer. Instituto de Biomedicina y Genética Molecular de Valladolid (IBGM). Consejo Superior de Investigaciones Científicas - Universidad de Valladolid (CSIC-UVa), Valladolid, Spain.ORCID https://orcid.org/0000-0002-9682-5589

Funding

Acción Estratégica en SaludConsejería de Educación, Junta de Castilla y LeónEscalera de ExcelenciaEuropean Regional Development Funds (European Union)Instituto de Salud Carlos III PI20/00110Instituto de Salud Carlos III PI20/00225Instituto de Salud Carlos III PI23/00047Instituto de Salud Carlos III PI24/00267Junta de Castilla y León CLU-2019-02Programa EstratégicoSpanish Ministry of Science and Innovation
6 · The paper itself

Abstract

Splicing dysregulation is a relevant mechanism of pathogenicity for variants in disease susceptibility genes. Variants affecting the critical intronic +1 and +2 GT nucleotides of the 5' splice sites (5'ss) are generally strong indicators of pathogenicity. However, some +2 T variants create functional noncanonical 5'ss that generate wildtype transcripts, hampering accurate variant interpretation and genetic counseling. We previously showed that variants PALB2 c.108+2T > C and ATM c.1898+2T > G generated significant levels of full-length (FL) transcripts by creating functional atypical GC and GG donor sites, respectively. In this study, we aimed to investigate the splicing impact of +2T variants in the breast cancer susceptibility genes ATM, BRCA1, and PALB2. For this purpose, five minigenes encompassing 29 exons of ATM, BRCA1, and PALB2 were employed. A total of 30 +2T > C/G/A variants were introduced into these constructs by site-directed mutagenesis and analyzed in MCF-7 cells. Four +2T > C variants (ATM c.6347+2T > C, BRCA1 c.5193+2T > C and c.5277+2T > C, and PALB2 c.2748+2T > C) and ATM variants c.6347+2T > A/G produced FL-transcripts (4%-81% of the overall expression). All +2T > C leaky variants conserved a central core of 6 nucleotides (AGgcaa). Variants were assessed according to the ClinGen specifications of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) interpretation guidelines. Two variants (ATM c.6347+2T > C and BRCA1 c.5193+2T > C) were classified as likely benign, consistent with predictions based on their respective ACMG/AMP-based gene specifications. Conversely, two variants (ATM c.6347+2T > G and BRCA1 c.4675+2T > C), initially predicted as likely pathogenic, were reclassified as variant of uncertain significance (VUS). In conclusion, a significant proportion of +2T variants can create functional noncanonical 5'ss, resulting in the production of FL-transcripts that may preserve gene function. Variant-splicing assays provide essential data for accurate clinical classification and for the development of effective clinical management strategies for patients and their families. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

Ataxia Telangiectasia Mutated ProteinsBRCA1 ProteinBreast NeoplasmsGenetic Predisposition to DiseaseRNA Splice SitesRNA SplicingFanconi Anemia Complementation Group N ProteinFemaleHumansMCF-7 CellsAtaxia Telangiectasia Mutated ProteinsATM protein, humanBRCA1 ProteinBRCA1 protein, humanFanconi Anemia Complementation Group N ProteinPALB2 protein, humanRNA Splice Sites+2T variantsaberrant splicinghereditary breast cancerminigenesnoncanonical splicingsusceptibility genesvariant classification

Identifiers

PMID41230741
PMCPMC12805630

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.